MCID: CHR043
MIFTS: 26

Chronic Inflammatory Demyelinating Polyneuritis

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuritis:

Name: Chronic Inflammatory Demyelinating Polyneuritis 12 15
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2536
ICD9CM 36 357.81
MeSH 45 D020277
NCIt 51 C84636
ICD10 34 G61.81
UMLS 74 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuritis, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to polyradiculoneuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuritis is PRF1 (Perforin 1), and among its related pathways/superpathways are Allograft rejection and Immune response Role of DAP12 receptors in NK cells. The drugs Immunologic Factors and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include thyroid.

Related Diseases for Chronic Inflammatory Demyelinating Polyneuritis

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuritis:



Diseases related to Chronic Inflammatory Demyelinating Polyneuritis

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuritis

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuritis

Drugs for Chronic Inflammatory Demyelinating Polyneuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
5 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Phase 2,Not Applicable
8 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 1
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
13 Pharmaceutical Solutions Phase 3,Phase 2
14 Fingolimod Hydrochloride Phase 3
15 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
16 Hormones Phase 3,Phase 1,Phase 2
17 Hormone Antagonists Phase 3,Phase 1,Phase 2
18 glucocorticoids Phase 3,Phase 1,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
21 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
22
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
23
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
24
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
25
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
26
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
27
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
28
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 50-18-0, 6055-19-2 2907
29
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
30
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
31
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
34 Trace Elements Phase 2
35 Antioxidants Phase 2
36 Vitamin B9 Phase 2
37 Thioctic Acid Phase 2
38 Alpha-lipoic Acid Phase 2
39 Vitamins Phase 2
40 Protective Agents Phase 2,Phase 1
41 Nutrients Phase 2
42 Vitamin B Complex Phase 2
43 Folate Phase 2
44 Micronutrients Phase 2
45 Antiviral Agents Phase 2
46 Anti-Infective Agents Phase 2
47 interferons Phase 2
48 Adjuvants, Immunologic Phase 2,Phase 1
49 Interferon-beta Phase 2
50 Antirheumatic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Panzyga in CIDP Administered at Different Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
6 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
7 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
8 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
9 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
10 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
11 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
12 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
13 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
14 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
15 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
16 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
17 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
18 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
19 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Active, not recruiting NCT02638207 Phase 3 NewGam
20 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
21 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
23 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
24 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
26 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT03861481 Phase 2 Rozanolixizumab
28 The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Recruiting NCT03864185 Phase 2
29 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
30 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
31 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
32 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
33 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
34 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
35 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
36 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
37 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
38 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
39 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
40 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
41 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
42 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
43 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
44 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
45 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
46 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
47 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
48 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
49 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733 Not Applicable
50 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuritis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: polyradiculoneuropathy, chronic inflammatory demyelinating

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuritis

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuritis:

42
Thyroid

Publications for Chronic Inflammatory Demyelinating Polyneuritis

Variations for Chronic Inflammatory Demyelinating Polyneuritis

Expression for Chronic Inflammatory Demyelinating Polyneuritis

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuritis.

Pathways for Chronic Inflammatory Demyelinating Polyneuritis

Pathways related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 FASLG IFNG PRF1
2
Show member pathways
11.91 FASLG IFNG PRF1
3
Show member pathways
11.79 FASLG IFNG
4
Show member pathways
11.75 FASLG IFNG
5
Show member pathways
11.58 FASLG IFNG
6
Show member pathways
11.42 FASLG PRF1
7
Show member pathways
11.36 FASLG IFNG
8
Show member pathways
11.28 FASLG PRF1
9 11.14 FASLG IFNG
10 11.06 FASLG IFNG
11 11.01 FASLG IFNG
12 10.89 FASLG IFNG
13
Show member pathways
10.62 IFNG PRF1
14
Show member pathways
10.58 FASLG IFNG PRF1
15 10.4 IFNG PRF1

GO Terms for Chronic Inflammatory Demyelinating Polyneuritis

Cellular components related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 8.92 FASLG IFNG KNG1 PRF1

Biological processes related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.33 FASLG IFNG PRF1
2 extrinsic apoptotic signaling pathway GO:0097191 8.96 FASLG IFNG
3 positive regulation of killing of cells of other organism GO:0051712 8.62 IFNG PRF1

Sources for Chronic Inflammatory Demyelinating Polyneuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....